Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annabelle Remoué

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Annales De Pathologie|January 7, 2022
[Rapid Idylla™ mutational testing: Current and future theranostic applications]Amélie Bourhis, Annabelle Remoué, Laura Samaison, et al.
Pathology|June 23, 2019
Avoiding non-contributive molecular results in cancer samples: proposal of a score-based approach for sample choiceAmélie Bourhis, Annabelle Remoué, Glen Le Flahec, et al.
Life (Basel, Switzerland)|February 25, 2023
The Histopathological "Placentitis Triad" Is Specific for SARS-CoV-2 Infection, and Its Acute Presentation Can Be Associated with Poor Fetal OutcomeAnnabelle Remoué, Yurina Suazo, Marie Uguen, et al.
La Revue De Medecine Interne|September 22, 2024
[Which workup should be performed after a pregnancy complicated with vasculo-placental disorder?]Claire de Moreuil, Annabelle Remoué, Jordan Pozzi, et al.
Human Pathology|November 27, 2020
Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™Annabelle Remoué, Virginie Conan-Charlet, Laura Deiana, et al.
Pathology International|February 2, 2019
Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expressionAnnabelle Remoué, Virginie Conan-Charlet, Amélie Bourhis, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 10, 2019
PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung CancersLaetitia Lambros, Isabelle Quintin-Roué, Amélie Bourhis, et al.
Pathology|September 14, 2021
Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencingAmélie Bourhis, Charline Caumont, Isabelle Quintin-Roué, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Annales De Pathologie|January 7, 2022
[Rapid Idylla™ mutational testing: Current and future theranostic applications]Amélie Bourhis, Annabelle Remoué, Laura Samaison, et al.
Pathology|June 23, 2019
Avoiding non-contributive molecular results in cancer samples: proposal of a score-based approach for sample choiceAmélie Bourhis, Annabelle Remoué, Glen Le Flahec, et al.
Life (Basel, Switzerland)|February 25, 2023
The Histopathological "Placentitis Triad" Is Specific for SARS-CoV-2 Infection, and Its Acute Presentation Can Be Associated with Poor Fetal OutcomeAnnabelle Remoué, Yurina Suazo, Marie Uguen, et al.
La Revue De Medecine Interne|September 22, 2024
[Which workup should be performed after a pregnancy complicated with vasculo-placental disorder?]Claire de Moreuil, Annabelle Remoué, Jordan Pozzi, et al.
Human Pathology|November 27, 2020
Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™Annabelle Remoué, Virginie Conan-Charlet, Laura Deiana, et al.
Pathology International|February 2, 2019
Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expressionAnnabelle Remoué, Virginie Conan-Charlet, Amélie Bourhis, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 10, 2019
PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung CancersLaetitia Lambros, Isabelle Quintin-Roué, Amélie Bourhis, et al.
Pathology|September 14, 2021
Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencingAmélie Bourhis, Charline Caumont, Isabelle Quintin-Roué, et al.
Pageof 1